DESIGNED TO BE DIFFERENT
by minimising off-target effects in the treatment of B-cell malignancies5–8
Proven efficacy regardless of line of
therapy, genetic status and patient
populations4,9–11
A consistent safety profile
demonstrated across B-cell
malignancies for over 5 years1,4,11–13
Unmatched BTK inhibitor
dosing flexibility1,14,15